Novel antibodies in the treatment of non-Hodgkin's lymphoma

Monoclonal antibodies (mAbs) have revolutionised the treatment of malignancies, especially non-Hodgkin's lymphoma (NHL). Antibody-based therapies target tumour cells expressing a specific antigen while sparing the majority of normal cells leading to a decrease in treatment-associated toxicity. Rituximab, a monoclonal antibody directed against CD20 on B cells, was the first monoclonal antibody to be approved by the US Food and Drug Association (FDA) in 1997 for the treatment of patients with relapsed/refractory, follicular or low-grade NHL . However, it was soon realised that not all patients respond to rituximab therapy and close to 60% of patients with follicular lymphoma who were previously sensitive to rituximab become 'resistant' to repeat rituximab therapy. This led to further attempts to improve the antitumour activity of anti-CD20 mAbs (i.e. 2nd/3rd generation anti-CD20s), and to identify additional potential targets on lymphoma cells other than CD20. A number of these antibodies directed against lymphoma cell targets other than CD20 are now undergoing development, many of which are currently in clinical trials. This manuscript focuses on an overview of these 'non-anti-CD20' novel mAbs for NHL.